Severe Candida albicans panophthalmitis treated with all available and potentially effective antifungal drugs: fluconazole, liposomal amphotericin B, caspofungin, and voriconazole.

Abstract

A severe case of Candida albicans panophthalmitis, probably prompted by an underlying diabetes mellitus, is reported. The course was prolonged (more than 16 weeks), although favourable after treatment with several antifungal agents, all with a predictable activity in this ocular complication and with proven susceptibility in the present case: fluconazole, liposomal amphotericin B, caspofungin, and voriconazole.

• Authors: Roberto Manfredi, Sergio Sabbatani
• Journal: Scandinavian journal of infectious diseases (Scand J Infect Dis) Vol. 38 Issue 10 Pg. 950-1 ( 2006) ISSN: 0036-5548 [Print] England
• PMID: 17008248 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antifungal Agents
• Echinocandins
• Lipopeptides
• Peptides, Cyclic
• Pyrimidines
• Triazoles
• liposomal amphotericin B
• Amphotericin B
• Fluconazole
• Caspofungin
• Voriconazole

Topics

• Amphotericin B (therapeutic use)
• Antifungal Agents (therapeutic use)
• Candida albicans
• Candidiasis (drug therapy)
• Caspofungin
• Echinocandins
• Fluconazole (therapeutic use)
• Humans
• Lipopeptides
• Male
• Middle Aged
• Panophthalmitis (drug therapy, microbiology)
• Peptides, Cyclic (therapeutic use)
• Pyrimidines (therapeutic use)
• Triazoles (therapeutic use)
• Voriconazole